Clinical Study Of Sanjiao Regular Sequence Therapy On Chronic Heart Failure

Objective: Observating impacts of Sanjiao Regular Sequence therapy on changes of living with heart failure questionnaire(LHFQ)scores,Pittsburgh sleep quality index(PSQI)scores,6 minute walk test distance,heart function classification,eadmission rate,mortality rate,left ventricular ejection fraction(LVEF),left ventricular end-diastolic internal diameter(LVEDD),left ventricular end-systolic dimension(LVESD),N-terminal pro-brain natriuretic peptide(NT-proBNP),high sensitive C reactive protein(hs-CRP)and endothelin-1(ET-1)of patients with chronic heart failure,to summarize the clinical curative effect of Sanjiao Regular Sequence therapy in patients with Yang deficiency syndrome of chronic heart failure type.Methods: 50 patients with chronic heart failure were randomly divided into 25 cases of control group and were given conventional western medicine treatment,without Chinese medicine treatment;25 cases of treatment group were given drugs used in the control group and Chinese medicine treatment of Sanjiao Regular Sequence therapy.The course of treatment in the two groups was 3 weeks.Observated changes of living with heart failure questionnaire(LHFQ)scores,Pittsburgh sleep quality index(PSQI)scores,6-minute walk test distance,heart function classification,eadmission rate,mortality rate,left ventricular ejection fraction(LVEF),left ventricular end-diastolic internal diameter(LVEDD),left ventricular end-systolic dimension(LVESD),NT-proBNP,hs-CRP and ET-1.And evaluated the safety of treatment methods by changes of the blood routine,urine routine,stool routine,liver function,renel function and electrocardiogram before and after treatment.Understanding the rate of reentry and mortality at the end of the treatment 120 days after the end of the treatment by follow-up.Results: The reduction of LHFQ scale in the treatment group was better than that of the control group(P<0.05),the patients in the treatment group PSQI lower than those in the control group(P<0.05),the increase of walking distance for 6 minutes in the treatment group was better than that in the control group(P<0.05),the improvement of cardiac function in the treatment group was better than that of the control group(P<0.05),the level of left ventricular ejection fraction in the treatment group was better than that of the control group(P<0.05),the lower diastolic end diastolic diameter of the left ventricular in the treatment group was better than the control group(P<0.05),the decrease of the end systolic diameter of the left ventricle in the treatment group is better than that of the control group(P<0.05),the reduction of NTproBNP,hs-CRP and ET-1 in the treatment group was better than that of the control group(P<0.05),the readmission rate of the patients in the treatment group was lower within 120 days than the control group(P<0.05),but there was no significant difference in mortality between the two groups within 120 days(P>0.05).Conclusions: Sanjiao Regular Sequence therapy on patients with chronic heart failure can improve the quality of life,improve the quality of sleep,heart increase the amount of exercise tolerance,improve heart function,reduce the level of NT-pro BNP hs-CRP and ET-1,increase left ventricular ejection fraction,decrease left ventricular end-diastolic internal diameter and left ventricular end-systolic dimension,and the safety is good,the rate of readmission can be reduced in 120 days,but there was no significant effect on mortality in 120 days.